supplementNot FDA-approvedResearch chemicalPramiracetam is not FDA-approved as a drug and is not a recognized dietary supplement ingredient in the US; it is sold in the US primarily as an unregulated research chemicalHuman trial data are limited to a small number of older studies in clinical populations (head injury, Alzheimer's disease) rather than healthy adults
PramiracetamBenefits, Dosage & Interactions
Pramiracetam is a synthetic nootropic compound belonging to the racetam family, first synthesized in the 1970s. It is a derivative of piracetam, with some structural modifications. Research on Pramiracetam focuses on cognition and mood. It is typically taken in the morning.
How much Pramiracetam do people take?
Cited trials used oral pramiracetam doses of roughly 400 mg twice daily (800 mg/day) to 1200 mg/day in divided doses. Route reported: Oral, as tablets in all cited studies. Frequency reported: Typically twice daily dosing in the cited head-injury and Alzheimer's trials. These are amounts documented in the cited studies and labels for Pramiracetam — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.
See the full reported protocol and its sourcesResearched by DoseRoutine Research TeamReviewed for accuracy by Nicholas Alexander, RSE, SO, PMPLast updated Educational reference only — not medical advice. Always confirm dosing and safety decisions with a licensed clinician.
Evidence: Mixed — 3 human studies published, with results that disagree.
Evidence strengthMixed · 2/4
PreclinicalStrong human evidence
3 human studies published, with results that disagree.
Plasma half-life
Not applicable
Typical timing
in the morning
Food rule
with food
Default unit
mg
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
- Reported amounts
- Cited trials used oral pramiracetam doses of roughly 400 mg twice daily (800 mg/day) to 1200 mg/day in divided doses[1][2][3][4]
Reported for Pramiracetam in the cited sources. Published ranges are not dosing advice.
References & evidence
Documents the Pramiracetam entry is written from. Each number matches an inline marker above.
- [1]Pharmacokinetics of oral pramiracetam in normal volunteersChang T, Young RM, Goulet JR, Yakatan GJ · Journal of Clinical Pharmacology · 1985 · Peer-reviewed · PMID 4008675
- [2]Placebo-controlled study of pramiracetam in young males with memory and cognitive problems resulting from head injury and anoxiaMcLean A Jr, Cardenas DD, Burgess D, Gamzu E · Brain Injury · 1991 · Peer-reviewed · PMID 1786500
- [3]Nootropic drugs in Alzheimer's disease: symptomatic treatment with pramiracetamClaus JJ, Ludwig C, Mohr E, Giuffra M, Blin J, Chase TN · Neurology · 1991 · Peer-reviewed · PMID 2011259
- [4]Pramiracetam effects on scopolamine-induced amnesia in healthy volunteersMauri M, Sinforiani E, Reverberi F, Merlo P, Bono G · Archives of Gerontology and Geriatrics · 1994 · Peer-reviewed · PMID 15374306
References & Evidence
Sources on this page that document Pramiracetam dosing, timing and safety.
- [1]National Center for Biotechnology Information View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is Pramiracetam studied for?
What is Pramiracetam?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
Pramiracetam is a synthetic nootropic compound belonging to the racetam family, first synthesized in the 1970s. It is a derivative of piracetam, with some structural modifications. Pramiracetam is primarily studied for its potential effects on cognitive functions, particularly memory formation and recall. Unlike some other nootropics, it is generally considered to have little to no sedative or stimulatory effects. It is available as a dietary supplement in some regions and is not currently approved by the U.S. Food and Drug Administration (FDA) as a drug for any medical condition, nor by the European Medicines Agency (EMA). Research into pramiracetam often focuses on its neuroprotective potential and its role in modulating specific neurotransmitter systems. Its development was initially influenced by a desire to find more potent or targeted cognitive enhancers compared to earlier racetam compounds.
What does the research say about Pramiracetam?
Tap a section to expand.
The precise mechanisms by which pramiracetam exerts its effects are not fully elucidated, but research suggests several pathways. One key proposed mechanism involves its influence on high-affinity choline uptake in the brain (as described by PubChem). This increased choline uptake is believed to make more acetylcholine available for neurotransmission, a neurotransmitter critical for learning and memory. Pramiracetam does not directly interact with cholinergic receptors; instead, its action is thought to be upstream, enhancing the raw material availability for acetylcholine synthesis. Another proposed mechanism relates to its potential impact on membrane fluidity and the activity of specific enzymes, though this area requires further investigation. Some studies suggest it may enhance the sensitivity of cholinergic receptors, leading to a more efficient use of available acetylcholine (as noted by Examine.com). It is important to understand that these mechanisms are based on preclinical and early-stage human research, and the full scope of its pharmacological actions is still being explored.
Source for this section: Sources for How does Pramiracetam work?: Jumps to this entry in the sources and references list at the end of the page.
Research on pramiracetam has primarily focused on its potential cognitive benefits, particularly in areas related to memory and learning. Animal studies and some preliminary human trials suggest potential improvements in memory consolidation and recall, especially in contexts of cognitive impairment (as per reports cited by DrugBank). For instance, some research has explored its use in individuals with memory deficits following brain injuries, showing promise in improving certain aspects of cognitive function. It has also been investigated for its potential to enhance long-term memory. While some users report subjective improvements in focus, learning capacity, and verbal fluency, these effects are largely anecdotal and have not been consistently demonstrated in robust clinical trials. The cognitive enhancing properties attributed to pramiracetam are generally linked to its proposed effects on cholinergic neurotransmission. However, it is important to note that most of the compelling evidence comes from studies on individuals with pre-existing cognitive impairments, and its benefits for healthy individuals are less clear and require further scientific validation.
The evidence base for pramiracetam's efficacy and safety in humans is relatively limited compared to more widely studied compounds. Much of the early research was conducted in the 1980s and 1990s and often involved animal models or small human trials, sometimes with methodological limitations (as reviewed by resources like Examine.com). For example, some studies explored its effects in patients with memory deficits due to electroconvulsive therapy or cerebral injury, showing some positive trends in cognitive scores. However, these studies were often small and not always designed to meet current standards for rigorous clinical trials. There are few large-scale, placebo-controlled, double-blind human trials sufficient to definitively establish its benefits for healthy individuals or for specific medical conditions. Current scientific consensus, as reflected by organizations like NIH ODS and MedlinePlus (which do not extensively cover pramiracetam), is that more robust and extensive research is needed to confirm its purported cognitive-enhancing effects and to fully characterize its safety profile in humans. Any claims of significant cognitive improvement should be viewed with caution until further high-quality human data become available.
Pramiracetam is generally considered to be well-tolerated in many individuals at commonly studied dosages, but like all compounds, it can cause side effects. The most frequently reported side effects include headache, gastrointestinal discomfort such as nausea or abdominal pain, and sometimes mild nervousness or agitation. Headaches are a common complaint with racetam compounds and are often attributed to increased demand for choline in the brain; these may sometimes be mitigated by co-administration with a choline source (as discussed in various user forums and some anecdotal reports). Less common side effects might include difficulty sleeping or drowsiness, though stimulation is not typical. Serious adverse events are rare based on existing literature, but comprehensive long-term safety data is not available. Any new or persistent side effects should prompt discontinuation and consultation with a healthcare professional. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Individuals considering pramiracetam should be aware of several warnings. Due to the limited long-term safety data in humans, prudence is advised, especially in extended use. Pregnant or breastfeeding women should avoid pramiracetam due to a lack of safety studies in these populations. Individuals with pre-existing medical conditions, particularly kidney or liver impairments, should exercise extreme caution and consult a healthcare professional before use, as the compound's metabolism and excretion pathway may be affected. Those with a history of seizures or psychiatric disorders should also consult a clinician, as the effects of pramiracetam on these conditions are not well-understood. It is also important to note that the purity and dosage of dietary supplements are not consistently regulated in all countries, increasing the risk of inconsistent product quality. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Pramiracetam is contraindicated for individuals with known hypersensitivity or allergy to pramiracetam or any racetam derivative. It is also contraindicated in severe renal impairment, as the kidneys are involved in its excretion, and severe impairment could lead to accumulation and potential toxicity. Due to the lack of sufficient research, it is contraindicated during pregnancy and lactation. While not an absolute contraindication, individuals with severe cardiovascular conditions, active bleeding disorders, or those undergoing surgery should exercise extreme caution and discuss with their healthcare provider due to theoretical risks or unknown interactions. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Specific clinically significant drug-drug interactions with pramiracetam are not well-documented in human studies. However, due to its proposed mechanism of increasing choline uptake and affecting acetylcholine levels, caution is advised when combining it with medications that also affect the cholinergic system, such as acetylcholinesterase inhibitors (e.g., donepezil, rivastigmine, galantamine) used for Alzheimer's disease, or anticholinergic drugs (e.g., scopolamine, tricyclic antidepressants which have anticholinergic effects). Combining with compounds that significantly alter neurotransmitter levels, particularly those affecting cognitive function or perception, should be done with extreme caution under medical supervision. As with many supplements, combining pramiracetam with central nervous system depressants or stimulants should be approached carefully, due to potential additive or paradoxical effects. Individuals taking anticoagulants should also be cautious, though no direct interaction has been established. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Pramiracetam is commonly studied at various doses, often taken in divided doses throughout the day. Typical administration often involves taking it in the morning, sometimes with a second dose later in the day, but avoiding late evening administration to prevent potential sleep disturbances, although this is not a prominent reported side effect. Some formulations are designed for once-daily dosing. It is generally recommended to take pramiracetam with food, particularly a source of fats, as it is a lipid-soluble compound, which may aid in its absorption. Individual needs vary — talk to a licensed clinician.
Source for this section: Sources for When should you take Pramiracetam?: Jumps to this entry in the sources and references list at the end of the page.
Put it into practice
Reading about Pramiracetam is the first step — DoseRoutine helps you act on it. These free tools turn what you just learned into a routine.
What interacts with Pramiracetam?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any glp1 + supplement | Note | Category ruleConfidence: theoretical | GLP-1 medications slow stomach emptying, changing how/when oral supplements absorb; rapid weight loss raises the importance of protein and micronutrients.Source pending | Time oral supplements when nausea is lowest; prioritize protein and micronutrients; discuss with your provider. |
| Any supplement + medication | Note | Category ruleConfidence: theoretical | Some supplements change how the body processes medications (absorption, liver enzymes, or additive effects).Source pending | Specific pairs are checked against a licensed drug database and shown with their own severity. Always confirm with your provider or pharmacist. |
Frequently asked questions about Pramiracetam
Pramiracetam is a supplement. The references summarized come from NIH and PubMed records, FDA labeling where it exists, and Mayo Clinic patient material.
Pramiracetam is commonly discussed in the context of supporting brain. Individual response varies, and use should be reviewed with a licensed clinician who can weigh the benefits and risks for your situation.
For Pramiracetam, it is typically taken in the morning and it is usually taken with food. Always follow the specific dose your clinician or the product label prescribes.
Pramiracetam carries potential side effects and drug interactions, documented in NIH, Mayo Clinic, and FDA label sources. Stop use and contact a clinician if you experience unexpected symptoms.
As a supplement, Pramiracetam can overlap with other supplements, prescription medicines, hormones and peptides. Because Pramiracetam is usually taken in the morning, most avoidable conflicts come from what else lands in that same window. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers Pramiracetam with no sign-up.
Whether Pramiracetam fits alongside testosterone replacement therapy depends on the protocol — dose, ester and ancillaries such as HCG or anastrozole — and on current bloodwork. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
"Peptides" is not one category — healing peptides, GLP-1 agonists, growth-hormone secretagogues and melanocortins each behave differently next to Pramiracetam. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
Published frequency for Pramiracetam varies by protocol and formulation, so the label or prescription is what sets it. It is typically taken in the morning. Most protocols have it taken with food. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
The effect of a missed dose of Pramiracetam depends on the protocol and formulation you are on. Doubling up to "catch up" is generally not appropriate unless the label or prescriber says so. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For Pramiracetam the useful record is the dose, the time it was actually taken, and what else was taken in the same window. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
Cited trials used oral pramiracetam doses of roughly 400 mg twice daily (800 mg/day) to 1200 mg/day in divided doses. Route reported: Oral, as tablets in all cited studies. Frequency reported: Typically twice daily dosing in the cited head-injury and Alzheimer's trials. These are amounts documented in the cited studies and labels for Pramiracetam — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.
Which studies looked at Pramiracetam?
Peer-reviewed research indexed in PubMed. Each entry links to the original record.
- 1.Placebo-controlled study of pramiracetam in young males with memory and cognitive problems resulting from head injury and anoxia(opens PubMed in a new tab)Brain Inj · 1991 · PMID 1786500 · https://pubmed.ncbi.nlm.nih.gov/1786500/
- 2.Pharmacokinetics of oral pramiracetam in normal volunteers(opens PubMed in a new tab)J Clin Pharmacol · 1985 · PMID 4008675 · https://pubmed.ncbi.nlm.nih.gov/4008675/
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- PubChem CID 51712(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/51712
Verify at
Publisher search links for Pramiracetam. These are places to check the information — they are not citations, so they are not numbered.
- Examine.com(publisher search, opens in a new tab)Examine.com · publisher search
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- DailyMed labeling archive(publisher search, opens in a new tab)U.S. National Library of Medicine · publisher search
- Wikipedia entry(publisher search, opens in a new tab)Wikipedia · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on Pramiracetam?
Plain-text summary, safe to quote verbatim:
Pramiracetam is a synthetic nootropic compound belonging to the racetam family, first synthesized in the 1970s. It is a derivative of piracetam, with some structural modifications. Research on Pramiracetam focuses on cognition and mood. It is typically taken in the morning.
Source: DoseRoutine — https://doseroutine.com/library/pramiracetam
Pramiracetam cheat sheet
DoseRoutine cheat sheet · Supplement
Pramiracetam
Pramiracetam is a synthetic nootropic compound belonging to the racetam family, first synthesized in the 1970s. It is a derivative of piracetam, with some structural modifications.
Evidence
Mixed
3 human studies published, with results that disagree.
Studied range
Cited trials used oral pramiracetam doses of roughly 400 mg twice daily (800 mg/day) to 1200 mg/day in divided doses
Route
Oral, as tablets in all cited studies
Frequency studied
Typically twice daily dosing in the cited head-injury and Alzheimer's trials
Half-life
Reported around 4.5–6.8 hours in the pharmacokinetic study by Chang et al.
Timing
in the morning
With food
with food
Not FDA-approvedResearch chemicalPramiracetam is not FDA-approved as a drug and is not a recognized dietary supplement ingredient in the US; it is sold in the US primarily as an unregulated research chemicalHuman trial data are limited to a small number of older studies in clinical populations (head injury, Alzheimer's disease) rather than healthy adultsBrain
Key references
Studied ranges, not dosing advice. Not medical advice — talk to a clinician. doseroutine.com/library/pramiracetam
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). Pramiracetam — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/pramiracetam
What compounds are similar to Pramiracetam?
Others in the supplement category or studied for the same goals.
Which goals is Pramiracetam used for?
Other compounds studied for the same benefits as Pramiracetam.
Continue exploring
See every compound DoseRoutine catalogs for these goals.